FBT - First Trust NYSE Arca Biotechnology Index Fund
| Assets | $1.88B |
| NAV | $161.07 |
| Expense Ratio | 0.55% |
| PE Ratio | 25.85 |
| Beta (5Y) | 1.02 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Sep 23, 2015 |
| 1-Year Return | - |
| Trading Day | April 20 |
| Last Price | $162.08 |
| Previous Close | $161.18 |
| Change ($) | 0.90 |
| Change (%) | 0.56% |
| Day's Open | 160.41 |
| Day's Range | 160.09 - 162.34 |
| Day's Volume | 72,213 |
| 52-Week Range | 146.10 - 186.51 |
Fund Description
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
| Asset Class Equity | Sector Biotech |
| Region Global | Inception Date Jun 19, 2006 |
| Exchange NYSEARCA | Ticker Symbol FBT |
| Index Tracked NYSE Arca Biotechnology Index | |
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...
As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on Inves...
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
Not all healthcare ETFs are the same and as this group of three proves, that can be a positive for savvy investors. The post 3 Healthcare ETFs to Buy for Health and Safety appeared first on InvestorPlace.
Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fund ...
Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.
Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ignor...
AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.
These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
The race to find a coronavirus vaccine is heating up as the latest positive data from progress in trials are being published.
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
In the continuing quest to find a vaccine for the coronavirus, the World Health Organization announced Wednesday it is dropping hydroxychloroquine, the malaria drug backed by President Trump, who claims...
While the Coronavirus pandemic continues dominating healthcare sector headlines, investors shouldn’t fret that biotechnology ETFs will be left vulnerable when the virus is finally vanquished. That’s goo...
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
Novavax's latest progress in the Covid-19 vaccine development brings optimism to the Wall Street.
We have presented a bunch of five top-performing ETFs of the 11-year bull market that will continue to outperform in the coming months given that these have a solid Zacks Rank.
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Companies in the biotech industry face an incredible amount of risk while getting their drugs to market.
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS: A...
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.
The U.S. economy has stepped into the 11th year of the expansion, exhibiting the longest expansion in history. These winning ETFs and stocks will rally further.
When the stock market is hitting record highs, it’s important to remember that it’s really a market of stocks rather than a stock market. Not all companies are created equal. Nor are all sectors.
M&A activity, approval of novel drugs and earnings growth in Q1 put healthcare ETFs in a decent spot.
